Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
复制标题
多发性骨髓瘤的嵌合抗原受体T细胞：迄今的旅程和未来的道路。
DOI：
10.1097/ppo.0000000000000506
复制
发表时间：
2021-03-01
期刊：
影响因子：
--
通讯作者：
Green DJ
中科院分区：
文献类型：
--
作者：
Cowan AJ;Tuazon SA;Portuguese AJ;Green DJ
Despite improvements in effective therapy, multiple myeloma remains incurable and virtually all patients will face relapsed disease at some point after diagnosis. The prognosis for relapsed myeloma after developing resistance to anti-CD38 monoclonal antibodies, proteasome inhibitors, immunomodulatory agents, and autologous stem cell transplantation has been poor; however, the development of immune-effector cell therapy with chimeric antigen receptor (CAR) T cells may dramatically improve the outlook for patients, though none of these therapies are approved for MM to date. Herein, we review the development and history of CAR T cell therapy for multiple myeloma, mechanisms of resistance, and strategies to improve outcomes with CAR T therapy.
